SEARCH

SEARCH BY CITATION

References

  • Batova, A., Diccianni, M.B., Yu, J.C., Nobori, T., Link, M.P., Pullen, J. & Yu, A.L. (1997) Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Research, 57, 832836.
  • Bennett, J.B., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A.G., Gralnick, H.R. & Sultan, C. (1982) Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology, 51, 189199.
  • Galton, D.A.G. (1986) The myelodysplastic syndrome. Scandinavian Journal of Haematology, 36, 1120.
  • Geddes, A.D., Bowen, D.T. & Jacob, A. (1990) Clonal karyotype abnormalities and clinical progress in myelodysplastic syndrome. British Journal of Haematology, 76, 194202.
  • Herbert, J., Cayuela, J.M., Berkeley, J. & Sigaux, F. (1994) Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood, 84, 40384044.
  • Herman, J.G., Merlo, A., Mao, L., Lapidus, R.G., Issa, J.-P.J., Davidson, N.E., Sidransky, D. & Baylin, S.B. (1995) Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Research, 55, 45254530.
  • Herman, J.G., Jen, J., Merlo, A. & Baylin, S.B. (1996a) Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Research, 56, 722727.
  • Herman, J.G., Graff, J.R., Myöhänen, S., Nelkin, B.D. & Baylin, S.B. (1996b) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proceedings of National Academy of Sciences of United States of America, 93, 98219826.
  • Herman, J.G., Civin, C.I., Issa, J.-P.J., Collector, M.I., Sharkis, S.J. & Baylin, S.B. (1997) Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Research, 57, 837841.
  • Hirama, T. & Koeffler, H.P. (1995) Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood, 86, 841854.
  • Iravani, M., Dhat, R. & Price, C.M. (1997) Methylation of the multi tumor suppressor gene-2 (MTS2, CDKN1, p15INK4B) in childhood acute lymphoblastic leukemia. Oncogene, 15, 26092614.
  • ISCN (1985) An International System for Human Cytogenetic Nomenclature (ed. by D.G.Harden & H.P. Glinger) Published in Collaboration withCytogenetics and Cell Genetics. Karger, Basel; also in Birth Defects: Original Articles Series, Vol. 21, No. 1 (March of Dimes Birth Defects Foundation, New York, 1985).
  • Jacobs, R.H., Cornbleet, M.A., Vardiman, J.W., Larson, R.A., Le beau, M.M. & Rowley, J.D. (1986) Prognostic implication of morphology and karyotype in primary myelodysplastic syndromes. Blood, 67, 17651772.
  • Kamb, A., Gruis, N.A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S.V., Stockert, E., Day, R.S.III, Johnson, B.E. & Skolnick, M.H. (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science, 264, 436440.
  • Knapp, R.H., Dewald, G.W. & Pierre, R.V. (1985) Cytogenetic studies in 174 consecutive patients with preleukemia or myelodysplastic syndrome. Proceedings of Mayo Clinic, 60, 507516.
  • Merol, A., Herman, J.G., Mao, L., Lee, D.J., Gabrielson, E., Burger, P.C., Baylin, S.B. & Sidransky, D. (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nature Medicine, 1, 686692.
  • Nobori, T., Miura, K., Wu, D.J., Lois, A., Takabayashi, K. & Carson, D.A. (1994) Deletions of the cyclin-dependent Kinase-4 inhibitor gene in multiple human cancers. Nature, 368, 753756.
  • Ogawa, S., Hangaishi, A., Miyawaki, S., Hirosawa, S., Miura, Y., Takeyama, K., Kamada, N., Ohtake, S., Uike, N., Shimazaki, C., Toyama, K., Hirano, M., Mizoguchi, H., Kobayashi, Y., Furusawa, S., Saito, M., Emi, N., Yazaki, Y., Ueda, R. & Hirai, H. (1995) Loss of cyclin-dependent kinase 4-inhibitor (p16; MTS 1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood, 86, 15481556.
  • Quesnel, B., Guillerm, G., Vereecque, R., Wattel, E., Preudhomme, C., Bauters, F., Vanrumbeke, M. & Fenaux, P. (1998) Methylation of the p15INK4B gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood, 91, 29852990.
  • Serrano, M., Hannon, G.J. & Beach, D. (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/DK4. Nature, 366, 704707.
  • Tien, H.F., Wang, C.H., Chuang, S.M., Chow, J.M., Lee, F.Y., Liu, M.C., Chen, Y.C., Shen, M.C., Lin, D.T. & Lin, K.H. (1994) Cytogenetic studies, ras mutation, and clinical characteristics in primary myelodysplastic syndrome – a study on 68 Chinese patients in Taiwan. Cancer Genetics and Cytogenetics, 74, 4049.
  • Tien, H.F., Tang, J.L., Lee, C.F. & Jou, S.T. (1998) Homozygous deletion of the p16INK4A gene occurs more frequently in CD2+ than in CD2 T-cell acute lymphoblastic leukemia. Blood, 91, 18291830.
  • Uchida, T., Kinoshita, T., Saito, H. & Hotta, T. (1997a) CDKN2 (MTS1/p16INK4A) gene alternations in hematological malignancies. Leukemia and Lymphoma, 24, 449461.
  • Uchida, T., Kinoshita, T., Nagai, H., Nakahara, Y., Saito, H., Hotta, T. & Murate, T. (1997b) Hypermethylation of the p15INK4B gene in myelodysplastic syndrome. Blood, 90, 14031409.
  • Wijermans, P., Lübert, M., Verhoef, G., Bosly, A., Ravoet, C., Andre, M. & Ferrant, A. (2000) Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high–risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. Journal of Clinical Oncology, 18, 956962.
  • Yunis, J.J., Rydell, R.E., Oken, M.M., Arnesen, M.A., Mayer, M.G. & Lobell, M. (1986) Refined chromosome analysis as an independent prognostic indicated in de novo myelodysplastic syndromes. Blood, 67, 17211730.